Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer

PURPOSE OF REVIEW: For decades, early-stage resectable non-small cell lung cancer (NSCLC), while potentially curable, has been marred by unacceptably high recurrence rates. RECENT FINDINGS: Anti-PD(L)1 immune checkpoint blockade (ICB) has revolutionized the treatment of advanced NSCLC, and with rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Parekh, Jay, Parikh, Kaushal, Reuss, Joshua E., Friedlaender, Alex, Addeo, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326100/
https://www.ncbi.nlm.nih.gov/pubmed/37249833
http://dx.doi.org/10.1007/s11912-023-01430-4
_version_ 1785069357451182080
author Parekh, Jay
Parikh, Kaushal
Reuss, Joshua E.
Friedlaender, Alex
Addeo, Alfredo
author_facet Parekh, Jay
Parikh, Kaushal
Reuss, Joshua E.
Friedlaender, Alex
Addeo, Alfredo
author_sort Parekh, Jay
collection PubMed
description PURPOSE OF REVIEW: For decades, early-stage resectable non-small cell lung cancer (NSCLC), while potentially curable, has been marred by unacceptably high recurrence rates. RECENT FINDINGS: Anti-PD(L)1 immune checkpoint blockade (ICB) has revolutionized the treatment of advanced NSCLC, and with recent approvals in the peri-operative space, is now poised to transform the systemic treatment paradigm for localized and locally-advanced NSCLC. SUMMARY: In this review, we focus on neoadjuvant ICB in resectable NSCLC, highlighting the pre-clinical rationale for neoadjuvant ICB, early clinical trials, randomized phase 3 trial data, and future directions for resectable NSCLC. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10326100
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-103261002023-07-08 Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer Parekh, Jay Parikh, Kaushal Reuss, Joshua E. Friedlaender, Alex Addeo, Alfredo Curr Oncol Rep Article PURPOSE OF REVIEW: For decades, early-stage resectable non-small cell lung cancer (NSCLC), while potentially curable, has been marred by unacceptably high recurrence rates. RECENT FINDINGS: Anti-PD(L)1 immune checkpoint blockade (ICB) has revolutionized the treatment of advanced NSCLC, and with recent approvals in the peri-operative space, is now poised to transform the systemic treatment paradigm for localized and locally-advanced NSCLC. SUMMARY: In this review, we focus on neoadjuvant ICB in resectable NSCLC, highlighting the pre-clinical rationale for neoadjuvant ICB, early clinical trials, randomized phase 3 trial data, and future directions for resectable NSCLC. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2023-05-30 2023 /pmc/articles/PMC10326100/ /pubmed/37249833 http://dx.doi.org/10.1007/s11912-023-01430-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Parekh, Jay
Parikh, Kaushal
Reuss, Joshua E.
Friedlaender, Alex
Addeo, Alfredo
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
title Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
title_full Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
title_fullStr Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
title_full_unstemmed Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
title_short Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
title_sort current approaches to neoadjuvant immunotherapy in resectable non-small cell lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326100/
https://www.ncbi.nlm.nih.gov/pubmed/37249833
http://dx.doi.org/10.1007/s11912-023-01430-4
work_keys_str_mv AT parekhjay currentapproachestoneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer
AT parikhkaushal currentapproachestoneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer
AT reussjoshuae currentapproachestoneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer
AT friedlaenderalex currentapproachestoneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer
AT addeoalfredo currentapproachestoneoadjuvantimmunotherapyinresectablenonsmallcelllungcancer

Ejemplares similares